US2017107267A1PendingUtilityA1
Peptide agonists of glp-1 activity
Est. expiryJul 12, 2019(expired)· nominal 20-yr term from priority
A61P 3/10A61K 47/62C07K 14/605A61K 38/00C07K 14/57563A61K 38/26A61P 3/04
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.
Claims
exact text as granted — not AI-modified1 - 48 . (canceled)
49 . A method for producing a peptide conjugate having a polypeptide sequence of the formula:
(SEQ ID NO: 118)
Lys 6 -Gly 8 -GLP-1 (7-36)-Lys 6 -NH 2
the method comprising the steps of:
a) introducing a nucleic acid sequence encoding the polypeptide sequence and a selectable marker contained within a nucleic acid construct or a vector into a host cell to obtain a recombinant host cell;
b) selecting said recombinant host cell;
c) culturing said recombinant host cells under conditions permitting the production of said polypeptide sequence;
d) isolating said polypeptide sequence from the culture; and
e) optionally cleaving said polypeptide sequence using an appropriate protease to obtain said peptide conjugate.
50 . A method of reducing mortality and morbidity after myocardial infarction in a mammal comprising administering to the mammal a peptide of the formula:
des Ala 35 -(Lys 40 (palmitoyl))exendin-4(1-39)-NH 2 (SEQ ID NO: 109), the free acid thereof, or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce mortality and morbidity after myocardial infarction.
51 . A peptide of the formula:
(Gly 8 ,Lys 37 (palmitoyl)-GLP-1(7-36)(Human)-Lys 7 -NH 2 (SEQ ID NO: 89), the free acid thereof and a pharmaceutically acceptable salts thereof.
52 . A method of treating a condition associated with elevated blood glucose levels in a mammal comprising administering to the mammal a peptide of the formula:
(SEQ ID NO: 88)
Gly 8 -GLP-1 (7-36)-Lys 6 -NH 2 ,
the free acid thereof, or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat the condition.
53 . The method of claim 52 , wherein the condition associated with elevated blood glucose levels is selected from type 1 diabetes, type 2 diabetes, insulin resistance syndrome, and hyperglycemia.Join the waitlist — get patent alerts
Track US2017107267A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.